HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trump Administration May Relax Supplement Industry Oversight, But Heighten Trade Concerns

This article was originally published in The Rose Sheet

Executive Summary

Supplement industry trade associations see positives in working with President-elect Trump, including his focus on business, but they also express concern with the possibility of restrictive trade prospects.

You may also be interested in...



Cosmetics Reg Reform Ill-Situated As Trump, FDA Explore 'Burden Reduction'

Any movement to advance proposed cosmetics reform legislation could be seen as running counter to President Trump's executive orders earlier this year, which now have FDA centers seeking "broad public comment" on how to achieve "meaningful burden reduction."

Got Ideas For Reducing Industry's Regulatory Burden? FDA Wants To Know

CFSAN and other FDA centers ask for "broad public comment" the agency will use "to guide our initial review of our regulations" required in President Trump's January executive order for federal agencies to "evaluate existing regulations and identify those that may merit repeal, replacement, or modification."

Herbalife Under SEC Scrutiny On Regulatory Compliance In China

Herbalife is the focus of a Securities and Exchange Commission investigation into anti-corruption compliance in the firm’s China business, the company reported in a Jan. 20 regulatory filing. An analyst covering the stock believes the investigation will have little impact on growth.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel